Table 1.
Demographic Data
| Variable | Patients = 296, HCCs = 457 |
|---|---|
| Age (years) | 61.4 ± 8.2 |
| Ethnicity | |
| Caucasian/white non-hispanic | 209 (209/296, 70.6%) |
| Black/African American | 37 (37/296, 12.5%) |
| Asian | 21 (21/296, 7.1%) |
| Hispanic | 21 (21/296, 7.1%) |
| Native American | 8 (8/296, 2.7%) |
| Cause of cirrhosis | |
| Hepatitis C | 144 (144/296, 48.6%) |
| Alcohol | 39 (39/296, 13.2%) |
| Alcohol and hepatitis C | 36 (36/296, 12.2%) |
| NASH | 27 (27/296, 9.1%) |
| Hepatitis B | 26 (26/296, 8.8%) |
| Cryptogenic | 17 (17/296, 5.7%) |
| Other* | 7 (7/296, 2.4%) |
| Sex | |
| Female | 64 (64/296, 21.6%) |
| Male | 232 (232/296, 78.4%) |
| HCC size (cm) | 3.5 ± 3.4 |
| Number of TACE treatments | 1.4 ± 0.7 |
| Selectivity of TACE treatments | |
| Lobar | 31 (31/457, 6.8%) |
| <Lobar, >segmental | 86 (86/457, 18.8%) |
| Segmental | 200 (200/457, 43.8%) |
| Sub-segmental | 140 (140/457, 30.6%) |
| WBC (109/L) | 5.4 ± 2.2 |
| Neutrophils (109/L) | 3.3 ± 1.9 |
| Lymphocytes (109/L) | 1.2 ± 0.7 |
| Hemoglobin (g/dL) | 12.6 ± 2.6 |
| INR | 1.2 ± 0.2 |
| Creatinine (mg/dL) | 1 ± 1 |
| Total bilirubin (mg/dL) | 1.3 ± 0.7 |
| Albumin (g/dL) | 3.2 ± 0.6 |
| MELD | 10.5 ± 3.5 |
| Child-Pugh score | 6.5 ± 1.3 |
| ECOG | 0.3 ± 0.5 |
| Alpha fetoprotein (ng/mL) | 28.6 (0–363, 848.3) |
Notes: *Other causes included hemochromatosis, primary biliary cirrhosis, autoimmune hepatitis, and cystic fibrosis. All numeric measures summarized as mean ± SD, except for AFP, which was summarized as median (range).
Abbreviations: HCC, hepatocellular carcinoma; NASH, non-alcoholic steatohepatitis; TACE, transarterial chemoembolization; cm, centimeter; ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell count.